GAMP 5 & CSA: A Practical Integration Guide for Pharma

Pharmaceutical manufacturers may use risk-based computerized-system assurance concepts, but FDA’s Computer Software Assurance (CSA) guidance is scoped to software used in medical-device production or quality management systems (^[1]). In parallel, ISPE’s updated GAMP 5 (Good Automated Manufacturing Practice) guidance (Second Edition, 2022) underscores the same risk-based, critical-thinking principles. This report provides a comprehensive analysis of how GAMP 5 and CSA align and how they can be integrated in practice by pharma IT teams. We review historical context and regulatory drivers (e.g. FDA’s final CSA guidance, issued February 3, 2026 and superseding the September 24, 2025 guidance, for software used in medical-device production or quality management systems), the principles of both GAMP 5 and CSA, and the practical steps to merge these frameworks into a cohesive validation strategy. Key themes include risk-based thinking, focus on intended use, scientific (critical) thinking over rote documentation, and leveraging supplier quality. The report compares traditional CSV vs. CSA approaches, outlines concrete implementation steps, and presents tables mapping CSA principles to GAMP 5 concepts. We include industry data (e.g. surveys showing knowledge gaps in CSA (^[2])) and expert viewpoints (from FDA guidance, ISPE publications, and thought leaders). Case examples illustrate how a GAMP/CSA approach can streamline validation without compromising product quality or patient safety. Finally, we discuss future directions—such as the impact of AI/machine learning, cloud computing, and digital transformation—on pharma computer systems assurance.

Pharmaceutical and life-sciences companies rely heavily on computerized systems for R&D, manufacturing, quality control, and clinical operations. Ensuring these systems operate reliably and produce trustworthy data is critical to patient safety and product quality. Historically, CSV has often used detailed documentation and testing to establish confidence that computerized systems are fit for their intended use. For pharmaceutical manufacturing, 21 CFR 211.68 requires routine calibration, inspection, or checking of applicable equipment; specified controls over computer systems and records; and appropriate validation data when computerized processes eliminate certain laboratory calculations (^[3]). The traditional CSV mindset has often equated more documentation with higher quality, leading to "great amounts of paper-based testing records" being generated in validation projects (^[4]). However, this documentation-heavy approach has come under scrutiny for being inefficient and not necessarily improving product quality or data integrity (^[5]) (^[4]).

In response to these inefficiencies, regulatory bodies and industry consortia have long advocated for risk-based, scientific approaches. For example, GAMP (Good Automated Manufacturing Practice) guidance was first published in the late 1990s to provide a flexible, risk-based framework for GxP (good practice) computerized systems. The first GAMP guidelines focused on categorizing systems and scaling validation effort, but still often implied heavy documentation. GAMP 5: A Risk-Based Approach (2008) was a landmark that explicitly emphasized risk management and the “quality by design” philosophy: identifying critical aspects of systems (those that impact patient safety, product quality, or data integrity) and focusing validation on them. Since its 2008 release, GAMP 5 has become the de facto industry standard for computerized system assurance globally (^[6]) (^[7]), although it is technically guidance (not a regulation).

GAMP 5 introduced five foundational principles rooted in risk-based thinking: understanding the product and process, operating within a quality management system (QMS), scalable validation lifecycles, science-based risk management, and a team effort emphasizing skilled personnel (^[8]) (^[9]). The Second Edition of GAMP 5 (published July 2022) maintains these core principles while updating them for modern technologies. Key enhancements include greater emphasis on service providers (e.g. cloud vendors), iterative/agile development models (such as Incremental/Continuous development), and new technology areas (^[10], blockchain, cloud computing, open-source software) (^[11]) (^[12]). Notably, GAMP 5 (2nd Ed) explicitly explores Computerized (Software) Assurance (CSA) as introduced by the FDA’s Case for Quality program, further reinforcing alignment with proactive risk-based assurance (^[13]).

FDA issued draft guidance “Computer Software Assurance for Production and Quality System Software” in September 2022. Its current final guidance, “Computer Software Assurance for Production and Quality Management System Software,” was issued on February 3, 2026 and supersedes the September 24, 2025 guidance. It also supersedes Section 6 (“Validation of Automated Process Equipment and Quality System Software”) of FDA’s 2002 General Principles of Software Validation guidance. The final guidance provides nonbinding, risk-based recommendations for computers and automated data-processing systems used in medical-device production or a medical-device quality management system; it does not establish pharmaceutical-manufacturing requirements (^[1]).

Collectively, these developments signify that “computer software assurance is a risk-based approach for establishing and maintaining confidence that software is fit for its intended use” (^[14]). The pharmaceutical industry therefore faces a change from conducting validation for its own sake to a mindset of critical thinking, process knowledge, and targeted assurance. As one review notes, GAMP’s concept of critical thinking — emphasizing planning and scientific reasoning before producing documentation — provides “the optimal replacement for [paper-based] computer system validation” (^[15]). This integration of CSA principles into GAMP 5’s risk-based lifecycle is intended to yield the same or better quality outcomes with less unnecessary effort (^[16]) (^[4]).

In this report, we will first review the detailed principles of GAMP 5 (Second Edition) and the FDA’s CSA guidance, then examine how they align. We will identify practical strategies for combining GAMP 5 and CSA into a single, risk-based validation/assurance program for computerized systems. We structure the report as follows:

• Regulatory and Historical Context: Overview of CSV/GAMP evolution and the impetus for CSA.
• GAMP 5 (Second Edition) Essentials: Key concepts, updates, and risk-management frameworks.
• Computer Software Assurance (CSA): The FDA guidance’s main messages and how CSA differs from traditional CSV.
• Aligning GAMP 5 with CSA: Mapping of CSA principles to GAMP 5 approach (including a table of comparisons).
• Practical Integration Guidelines: Practical considerations for pharma IT teams; FDA CSA directly applies to software used in medical-device production or a medical-device quality management system, and pharma organizations should first determine the requirements applicable to their products and jurisdictions.
• Data and Case Examples: Survey results, expert opinions, and illustrative scenarios showing benefits and challenges.
• Implications and Future Directions: Impact on quality culture, technology adoption (cloud, AI/ML), and ongoing regulatory modernization.
• Conclusion: Summary of best practices and concluding recommendations.

Inline citations identify sources for selected regulatory, industry, and illustrative statements.

GAMP 5 Philosophy and Lifecycle

GAMP 5 (Second Edition, 2022) is the latest version of the ISPE’s internationally recognized guidance on GxP computerized systems (^[17]) (^[7]). Its core philosophy is that "quality cannot be tested into a system", but instead must be built in via a risk-based, scientifically grounded process. GAMP 5 asserts that companies should use “critical thinking” and leverage their product/process knowledge to tailor validation efforts to actual risk (^[15]) (^[13]). In practice, this means identifying the “intended use” of each system, assessing how failures could affect patient safety, product quality or data integrity, and then applying resources to those high-risk areas.

GAMP 5 endorses a lifecycle approach to computerized systems, from concept through retirement, integrated within the site’s Quality Management System. Unlike a one-size-fits-all “V-model” used in older guidance, GAMP 5 explicitly calls for scaled life cycles. In the Second Edition, categorization is applied to individual components rather than used as a prescribed whole-system validation class. Organizations combine component categorization with GxP impact, complexity, novelty, risk assessment, and supplier assessment to scale life-cycle activities (^[18]).

Key to the GAMP 5 risk-based lifecycle is the focus on product and process understanding. Before specifying requirements, teams must deeply understand what critical attributes of the product/process the system supports (^[8]) (^[19]). This ensures that validation targets the most significant features and avoids wasting effort on irrelevant functionality. Throughout development and deployment, science-based quality risk management is applied (Section 5.2 of GAMP 5) (^[20]). In other words, risks are identified and mitigated (or accepted) using objective analysis rather than rote checklists, and decisions are documented in risk logs or similar formats.

GAMP 5 also strongly encourages leveraging existing resources and knowledge. For example, when using off-the-shelf commercial software, much of the testing burden can be reduced by appropriate supplier assessment and documentation review (^[9]) (^[21]). GAMP 5’s supplier involvement concept allows the industry to trust qualified vendors: if a vendor has a certified quality system and provides usage documentation, the end user need not retest every detail. Moreover, GAMP allows for the use of automation and modern tools to enhance assurance. The Second Edition explicitly references emerging technology areas (AI/ML, cloud, etc.) and expects critical thinking by appropriately skilled Subject Matter Experts (SMEs) to guide the use of these technologies (^[12]). Fundamentally, GAMP 5 (2nd Ed) preserves the mantra that “the ‘C’ in CGMP stands for Current,” meaning companies should use modern validated approaches to achieve compliance (^[22]), in line with FDA’s expectation of science-based flexibility.

To summarize, some central concepts of GAMP 5 (Second Ed) relevant to CSA integration are:

• Risk-Based Scaled Lifecycle: Activities (requirements, design, verification) are tailored by risk. Large changes to control logic get more testing; minor config changes get less (^[9]).
• Quality Risk Management (QRM): Formal QRM is applied throughout. Sections 5.2 and 6.0 discuss using risk analyses to decide “what to test” and to control systems during operation.
• Critical Thinking: Emphasized in GAMP 5; SMEs use process knowledge to choose effective validation strategies rather than following a fixed script (^[15]). This means asking “what could go wrong?” rather than “what can we test against?”
• Supplier/Vendor Focus: GAMP encourages leveraging supplier evidence and involvement. Supplier assessment and the documented risks associated with system components inform the appropriate use of supplier evidence; categorization is only one factor and does not prescribe validation work (^[18]).
• Automation and Tools: The 2nd Edition specifically acknowledges advanced technologies. Automation (e.g. automated testing tools) is seen as a way to “help software development and testing” (^[23]). The use of computerized tools for document management, testing, and monitoring fits well into GAMP’s QMS integration.

Software Categories (GAMP 5)

GAMP 5 Second Edition treats categories as a way to understand the likelihood of residual defects in individual software components—not as fixed whole-system risk classes or a validation checklist. Its component groups include infrastructure software, tools and IT services; standard system components; configured components; and custom applications and components. A computerized system commonly combines components from more than one group.

Organizations should use categorization with critical thinking, GxP impact, risk assessment, and supplier assessment to scale lifecycle activities. The appropriate effort depends on the overall GxP impact, component complexity and novelty, and identified risks; it cannot be prescribed solely from a category label (^[18]).

The July 2022 revision of GAMP 5 explicitly acknowledges the move toward CSA and modern software methods. The guide highlights “the importance of critical thinking and the application of patient-centric, risk-based approaches… versus primarily compliance-driven approaches” (^[12]). It also includes new content on cloud service providers and AI/ML. Significantly, the GAMP 5 Second Edition “explores and applies” CSA concepts as discussed by FDA’s Case for Quality program (^[13]). In other words, GAMP 5 (2nd Ed) has been written expecting readers to use CSA-like thinking: focusing on product/application function, identifying high-risk features, employing agile testing, and integrating supplier quality into the validation strategy.

ISPE leadership has affirmed that GAMP 5 (2nd Ed) is fully aligned with FDA’s emerging CSA guidance (^[17]). The ISPE GAMP Community states that the “fulfilling the objectives of the CSA draft guidance can be fully achieved by applying GAMP 5 (Second Edition).” (^[16]). They note that both emphasize “critical thinking based on product/process knowledge”, strong quality risk management, and a focus on true quality over rote compliance (^[16]). Thus, in principle, a properly executed GAMP 5 framework already covers CSA’s goals, and integrating the two chiefly involves recognizing this alignment and adjusting practices accordingly (e.g., explicitly using the CSA terminology of “assurance” and incorporating new testing flexibilities).

Purpose and Scope of the CSA Guidance

FDA issued its final guidance, “Computer Software Assurance for Production and Quality Management System Software,” on February 3, 2026; it supersedes the September 24, 2025 guidance. The final guidance gives nonbinding recommendations for computers and automated data-processing systems used in medical-device production or a medical-device quality management system. It discusses cloud computing, automated workflows, data-analytics tools, and AI/ML when used in that scope; it does not establish pharmaceutical-manufacturing requirements (^[1]).

The core message of the FDA CSA guidance is succinctly phrased in its introduction:

“Computer software assurance is a risk-based approach for establishing and maintaining confidence that software is fit for its intended use.” (^[1]).

The guidance emphasizes that manufacturers should tailor validation efforts to the risk posed by the software failing. In particular, it encourages focusing effort on features and operations of highest process risk, and using a least-burdensome approach so that validation burden is “no more than necessary to address the risk” (^[14]). Other key points include:

• Intended Use Definition: Clearly define the intended use of each software feature or function. Assurance activities should directly target meeting those intended uses.
• Risk Assessment-Based Effort: Conduct a quality risk management assessment that considers the harm to product quality or patient safety if software fails. For each in-scope feature, function, or operation, document the intended use and risk-based analysis, then select assurance activities and records commensurate with that analysis. For a low-risk intended use, supplier evidence and initial installation and configuration activities may sometimes be sufficient to establish confidence.
• Emphasize Prevention: Focus on preventing defects rather than detecting them after the fact. For instance, incorporate software quality assurance during development (e.g. code reviews, static analysis) to reduce defects early.
• Flexible Testing: Allow using a variety of testing approaches. This includes unscripted or exploratory testing centered on critical functions, rather than exhaustive scripted tests covering all possible paths (^[24]). The guidance explicitly acknowledges that traditional test scripts (hundreds of pages of click-by-click instructions) are often inefficient and contribute to deviations.
• Leverage Existing Evidence: Recognize and utilize existing data and documentation. For example, do not duplicate full revalidation of software that is purchased from a reputable vendor with strong quality systems. This is sometimes called the trusted supplier concept (^[23]).
• Technology and Automation: Promote automated, auditable testing (e.g. automated unit tests, regression tests, continuous monitoring) where practical, to increase efficiency and reproducibility.

In summary, the CSA guidance urges industry to move away from a document-driven check-box mentality (“validation-for-paper’s-sake”) toward a quality-driven, risk-focused process. FDA describes the guidance as nonbinding recommendations and states that it does not establish legally enforceable responsibilities; an alternative approach may be used if it satisfies applicable statutes and regulations (^[1]).

CSA vs. Traditional CSV

Traditionally, CSV in pharma has involved creating detailed requirements, design, test, and change-control documents, regardless of actual risk. CSA reframes this by asking: which validations are truly necessary? Table 1 below contrasts key differences between the legacy CSV approach and a GAMP/CSA approach.

Table 1. Comparison of Traditional CSV (prescriptive) versus CSA/GAMP 5 (risk-based) approaches. Sources: FDA CSA Guidance (^[14]), ISPE GAMP 5 guidance (^[26]) (^[16]), and industry commentaries (^[5]) (^[28]).

Key insights from Table 1 include:

• Risk focus: Unlike broad CSV, CSA/GAMP explicitly uses risk management as the driver (^[26]). The FDA states that risk-based CSA is “least-burdensome” and anticipates only necessary validation (^[14]).
• Critical thinking vs. documentation: Both GAMP and CSA emphasize “quality over quantity” of documentation. A PharmaEE article bluntly notes that “a mountain of paperwork did not equate to proper CSV” (^[5]) and that critical thinking replaces mindless checking. This reduces effort and exposes real issues like data integrity gaps, rather than just proving boxes were ticked.
• Leverage automation: CSA explicitly mentions using automated tools, which aligns with GAMP 5 encouraging modern approaches (e.g. software tools for testing and monitoring). Google Cloud’s experience notes how Infrastructure-as-Code and CI/CD pipelines can automate GxP testing and traceability (^[29]).
• Supplier evidence: FDA permits manufacturers to consider validation activities performed by developers, suppliers, and cloud service providers. Manufacturers should evaluate vendors and retain objective evidence using a risk-based approach; FDA does not create a general status of “FDA-qualified software” (^[1]).
• Terminology shift: The renaming from “validation” to “assurance” in FDA’s guidance is significant. GAMP 5 authors applaud this, calling it a logical expansion of scope (covering lifecycle and governance) (^[27]). The broader term “assurance” signals the change in mindset from static validation to continuous confidence.

In practice, applying CSA means redefining the validation plan. Instead of planning one huge validation project, teams map out “assurance activities” keyed to risk. For example, a critical feature might still have a formal protocol and report, whereas an unquestioned configuration might have only a checklist review. This agility requires experienced personnel who can judiciously determine where documentary evidence is necessary (^[15]).

Given the strong conceptual overlap, GAMP 5 and CSA are best viewed as complementary. ISPE and FDA sources emphasize that no fundamental conflict exists – rather, GAMP 5 (2nd Ed) already embodies CSA’s philosophy (^[17]) (^[16]). Key alignments include:

• Risk-Based Assurance: Both insist on risk management. GAMP 5 Section 5.2 describes Science-Based Quality Risk Management; CSA guidance reinforces applying this at the software feature level (^[20]). As the CSA guidance states, testing must be prioritized by patient/process risk – exactly GAMP’s approach. (^[20]) (^[14])
• Critical Thinking: GAMP 5 explicitly promotes critical thinking as good practice. CSA also urges prioritizing rationale over rote procedure. For example, GAMP Good Practice Guides and GAMP 5 introduced “critical thinking” as a term; FDA’s CSA uses it even if not by name (e.g. “scientifically sound” approach (^[30])). Wherever CSA might omit the buzzword, GAMP steps in as the detailed roadmap. (^[16]) (^[15])
• Suppliers and Existing Evidence: GAMP encourages supplier engagement (Cat 3/4) and re-use of vendor docs. CSA explicitly endorses using a supplier’s certified systems as evidence (^[23]). They both discourage unnecessary duplication of vendor validations.
• Agile/Flexible Testing: GAMP 5 recognizes iterative and agile dev. CSA envisions similar flexibility (e.g. unscripted testing). Both support shifting some work to production monitoring (continuous oversight) rather than upfront scripts.
• Terminology & Culture: Use of “assurance” rather than “validation” is essentially semantic, but it highlights FDA’s openness to innovation (^[27]). GAMP’s use of “life cycle” and “assurance” language shows the concept is already built-in, though older companies may still label processes “validation.” The practical effect is to encourage organizations to break from outdated paper-heavy mindsets and adopt the risk-based GAMP approach throughout.

Table 2 (below) illustrates several CSA principles from the FDA final guidance side-by-side with the corresponding GAMP 5 concepts or sections that support them.

Table 2. Mapping of CSA concepts to GAMP 5 (2nd Ed) practices. FDA’s final February 2026 CSA guidance describes a risk-based approach to establishing confidence in software used in medical-device production or quality management systems, including intended-use evaluation, risk-based assurance activities, multiple testing methods, continuous monitoring, and consideration of supplier evidence (^[1]).

As Table 2 indicates, nearly every CSA principle has a GAMP 5 counterpart. For example, CSA’s emphasis on preventing defects aligns with GAMP’s requirement to use a QMS-driven lifecycle (review gates, risk controls) to prevent errors rather than discover them via test. CSA’s focus on high-risk features is just GAMP’s science-based risk management applied to software validation. Even the language change from “validation” to “assurance” is anticipated in GAMP’s guidance on life-cycle activities and operations (^[27]).

Indeed, the ISPE GAMP Community explicitly supports FDA’s move toward CSA terminology. They note that replacing “validation” with “assurance” “is logical as it covers all the essential life cycle, operational, and governance activities involved” (^[27]). Thus, there is essentially no conflict between CSA and GAMP 5; rather, CSA can be seen as the FDA’s way of underlining approaches GAMP already encourages.

For pharma IT teams, the relevant question is how GAMP-informed, risk-based computerized-system assurance practices fit their own applicable GxP requirements. FDA CSA is not a pharmaceutical-manufacturing requirement; organizations should first determine whether they manufacture medical devices, combination products, drugs, or biologics and identify the applicable jurisdiction-specific requirements. The following considerations are illustrative rather than instructions to implement FDA CSA for pharmaceutical manufacturing.

1. Establish Governance and Training:

• After determining applicable product and jurisdictional requirements, update policies/procedures where appropriate to reflect the organization’s documented risk-based assurance approach. Do not treat FDA CSA terminology or document names as a pharmaceutical requirement. Ensure IT and Quality have a shared understanding of “critical thinking” and risk-based methods (^[15]) (^[16]).
• Provide training on GAMP 5 (2nd Ed) and CSA guidance, emphasizing how the new approach differs from tradition. Encourage a quality mindset that values insight over paperwork. As noted in surveys, lack of CSA knowledge is a major barrier (^[2]), so investing in education is crucial.

1. Inventory & Segmentation:

• Identify all computerized systems in scope (GxP and supporting). For each system, document its intended use, functions, user base, and GxP impact. Assess the individual components using the Second Edition groups together with complexity, novelty, supplier assessment, and documented risk; do not use a category as a whole-system validation class (^[31]).
• Example: A regulatory lab LIMS may have a high impact on product release, while a general document-management system may have lower GxP impact. The inventory and documented assessment inform the proportionate assurance activities for each system.

1. Risk Assessment and Life-cycle Planning:

• For each system, perform a Quality Risk Assessment (QRA) at the outset. The QRA should consider:
• Risk if software fails: Impact on patient safety, product yield, regulatory compliance. (GAMP calls this “Patient safety, product quality, data integrity.”)
• Complexity and novelty: New or highly customized systems add risk; routine updates or well-known vendor software add less risk.
• Components and supplier evidence: The complexity and novelty of individual components, their likely residual defects, supplier assessment, and how each component contributes to identified system risks. A whole-system assessment of the main component may inform supplier assessment, but it does not determine life-cycle activities (^[31]).
• Use the QRA to decide development/qualification strategy:
• Will assurance use fully detailed or exploratory protocols, and how will supplier evidence supplement the organization’s own documented assurance activities?
• Are we building custom code (thus need Dev QA) or buying COTS with vendor validation documents?
• Document the strategy in the organization’s established plan or record; it may use a Software Assurance Plan or Validation Plan, as appropriate to applicable requirements and procedures. The record should state which functions will receive what level of attention and why, based on risk (^[1]).

1. Supplier Qualification and Documentation:

• Evaluate suppliers using procedures proportionate to risk; the assessment may include the supplier’s development lifecycle, quality-management system, relevant certifications, cybersecurity documentation, and infrastructure support.
• Vendor documentation and test evidence may contribute to assurance, but certifications and supplier evidence alone do not establish that the user’s configured system is fit for its intended use.
• Before reducing user-side assurance activities, document a risk-based assessment of intended use, configuration, interfaces, infrastructure, and applicable data-integrity requirements, then perform assurance activities commensurate with the identified risk.

1. Critical-thinking Reviews:

• Convene cross-functional Subject-Matter Experts (from Quality, IT, Engineering, Operations) to review the system’s intended use and risk assessment. Apply critical thinking to ask: “What could go wrong? Where must we be absolutely sure the system works?”
• For each high-risk feature, define clear acceptance criteria. For example, a calculation function might require numerical accuracy testing; an audit trail function requires testing by altering data and seeing the result.
• Document this analysis (e.g., a Critical Review Memo or risk remarks). Importantly, focus documentation on decisions, not test steps. This approach mirrors GAMP 5 good practice of capturing risk and rationale, rather than printing every test screen.

1. Verification and Testing:

• Risk-based test scope: For each in-scope feature, function, or operation, document intended use and the risk-based analysis, then select assurance activities and records sufficient to establish confidence. Low-risk intended uses may be supported by appropriate existing evidence and initial installation/configuration activities; critical paths (e.g. data entry or signature) require targeted assurance commensurate with their risk.
• Flexible testing types: For medical-device production or quality-management-system software within FDA CSA’s scope, select testing methods appropriate to intended use and risk; FDA describes both scripted and unscripted testing among methods that may be used (^[1]).
• Automation: Employ automated test scripts or tools where available to improve coverage and repeatability (especially for regression tests). For example, use automated data migration tests or audit-trail verifications. This aligns with GAMP 5’s encouragement of tools and CSA’s support for automation.
• Monitor in Operation: Plan for continuous assurance. Instead of finalizing test artifacts that sit unused, implement real-time or periodic data monitoring. Activities like production monitoring or statistical alarms become part of assurance.
• Documentation: Instead of exhaustive test run records for every step, produce summary documentation that shows: what was tested, what the results were, and that acceptance criteria were met. For instance, a Test Summary Report focusing on high-level results. Keep proof-of-testing to what adds confidence (e.g. screenshots of critical tests) (^[25]), not dozens of printouts.

1. Change Management:

• Apply the same risk-based thinking to changes. Minor changes to low-risk systems might need only a brief review. Significant changes (new modules, upgrades) require full impact assessment and assurance activities.
• GAMP 5 and CSA both emphasize continuous compliance. Maintain updated risk assessments after each change. Under CSA, even minor updates can often be handled by augmenting existing test cases rather than revalidating from scratch, as long as critical functions remain intact.

1. Quality Oversight and Release:

• Assemble all assurance documentation (plans, risk assessments, test summaries) into a Validation/Assurance Report. The report should explicitly tie back to risk: e.g. “We tested Scenario X because its failure would cause Y hazard; test results show it meets acceptance criteria.”
• Have QA review focus on the logic and risk decisions, not on quotas of documents. Ensure that patient-safety and data integrity issues (as identified in risk) have been addressed.
• Prepare for audits by being able to justify the “why” of your approach: e.g. if you did only 2 test cases on a function, show the risk analysis that deemed more unnecessary. Regulatory inspectors have indicated that risk-based flexibility is acceptable as long as it is well-justified (^[16]).

1. Post-Implementation Assurance:

• Even after the system goes live, maintain a proportionate level of monitoring. This might include periodic checks of audit logs, data integrity reviews, or performance metrics.
• Re-run risk assessments periodically or when business processes change, ensuring that new risks haven’t arisen. Document any residual risks and controls.

This integration process can be visualized as a hybrid life-cycle where GAMP’s structured stages remain, but every stage is informed by CSA’s risk-centered philosophy. IT validation templates and SOPs may need updating to reflect CSA terminology (e.g. replacing “validation summary” with “assurance summary” and including risk evaluation sections). However, the core GAMP cycle (User Requirements → Build/Configure → Test → Operational) is intact; it is simply executed in a smarter way.

Adopting a new paradigm requires evidence that the old ways were indeed inefficient or insufficient, and that the new way can work. Several sources illustrate the need for CSA/GAMP methods:

• Regulatory Guidance and Analysis: FDA’s final CSA guidance recommends a risk-based approach to establish confidence in software used in medical-device production or quality management systems, including selecting assurance activities and records commensurate with risk (^[1]).
• Industry Surveys: A 2024 GAMP workshop poll (71 industry respondents) found only 14% had a strong understanding of CSA, with 31% having no knowledge and 55% unclear about how CSA differs from CSV (^[2]). This highlights that adoption is still low, reinforcing the need for broad education and pilot projects.
• Expert Commentary: Thought leaders have noted that rigid CSV has become an obstacle. As Technology Networks author Bob McDowall summarized, CSV often yielded “great mountains of paper” yet frequently failed to ensure data integrity or safety (^[5]) (^[32]). In contrast, preliminary implementations of CSA in industry (though still not widespread) report achieving compliance more efficiently. For instance, one Google Cloud case study notes that transitioning to CSA and cloud integration “directly realiz [es] the efficiency goals of CSA”, through shared controls and automation (^[29]).
• Data Integrity Considerations: A risk-based assurance program should identify foreseeable failures that could affect data integrity, product quality, or patient safety and select controls and evidence commensurate with those risks.
• Market and Trend Data: This article does not rely on a quantitative market forecast for CSV or CSA adoption.

Example: Risk-Based Testing Reduces Effort

A hypothetical case illustrates the benefits. Consider a legacy pharmaceutical manufacturing execution system (MES). Under traditional CSV, the validation team might write 200+ pages of test protocols covering every screen/button, run exhaustive tests, and produce a massive report. In a CSA/GAMP approach, the team instead maps out the intended use (e.g. tracking batch records, controlling critical process parameters) and identifies the handful of functions whose failure would trigger critical quality issues. They design perhaps 10–20 focused tests (covering batch issuance, coordinates with critical QC tests, final batch release) and deploy automated checks (e.g. a script that injects a data point to test the audit trail). They trust that fundamental system integrity is supported by the vendor’s built-in checks and QA. The amount and type of testing should be determined by documented risk analysis and intended use; the FDA guidance does not establish a fixed percentage reduction in test volume or audit outcomes.

Case: Risk-Based Assurance Concepts in a Biotech LIMS Background: This hypothetical case applies risk-based assurance concepts illustratively. FDA CSA directly applies only when software is used in medical-device production or a medical-device quality management system; a pharma organization must determine its own applicable requirements. A biotech company had a legacy LIMS for QC labs. The LIMS included configured components and supported critical stability-data activities. Traditionally, the CSV required a full-scale protocol of ~150 test cases and extensive documentation. Under a risk-based GAMP-style approach:

• The Quality and IT leads first defined the LIMS intended use precisely: “Capture test results, enforce review workflow, and maintain audit trail for stability program.” They listed the key functionalities supporting this use (e.g. data queries by sample, sign-off process, audit log).
• They performed a risk assessment: A failure in calculations (e.g. assay result) would be high risk; a missing hyperlink on the menu page was low risk. They determined to focus on validating calculations, data integrity, and audit trail, while spending minimal effort on trivial UI elements.
• Vendor documentation (including recent version-release test reports) was reviewed as part of supplier evaluation. Before reducing user-side assurance, the team documented the LIMS’s intended use and assessed the configured functions, interfaces, infrastructure, and data-integrity risks; it then selected assurance activities proportionate to those risks.
• The team prepared ~30 test cases (with expected pass/fail) covering all high-risk cases (e.g. editing a result triggers audit event) and a few critical moderate-risk flows. They did not script navigation through every menu path. Some exploratory testing sessions were held with SMEs to see if any obvious defect emerged; none did.
• The resulting validation report was ~10 pages, focusing on summary of risk, verification results, and a single-page log of any test anomalies (there were none).
• In a real implementation, project duration and inspection outcomes would depend on the organization, system, risk assessment, and applicable regulatory requirements; this hypothetical example does not assert either result.
• Going forward, the LIMS’s maintenance plan included periodic data audits and a review of the risk assessment when processes changed, rather than re-writing massive protocols for every minor upgrade.

This hypothetical case illustrates how risk-based assurance concepts can be considered within a GAMP-style life cycle, while the applicable regulatory requirements remain organization- and product-specific.

The integration of GAMP 5 and CSA touches not just validation procedures but broader manufacturing and IT strategy. Several implications and upcoming trends are noteworthy:

• Regulatory Acceptance and Global Harmonization: FDA issued final CSA guidance on September 24, 2025. FDA issued its current final guidance on February 3, 2026, which supersedes the September 2025 guidance. It represents FDA’s nonbinding current thinking for software used in medical-device production or a medical-device quality management system, rather than a pharmaceutical regulatory expectation (^[33]). ISPE continues to reaffirm alignment between GAMP 5 (2nd Ed) and CSA (^[17]), and there is no indication of pushback from regulators. Other agencies (EMA, PMDA, PIC/S) have historically recognized GAMP 5 as guidance (^[34]), and they too encourage quality risk management. We may see PIC/S or EMA issue similar CSA-type guidance in the future. For medical-device production and quality-management-system software, FDA describes CSA as a nonbinding, risk-based approach that may be used to provide objective evidence for applicable requirements; organizations must still determine and meet the requirements that apply to their products, operations, and jurisdictions. Notably, regulators have long stressed that CGMPs are minimum requirements and encourage companies to exceed them with modern quality systems (^[22]). CSA is aligned with that shift.

• Cultural Shift: Integrating CSA requires a mindset change. Quality professionals who learned to trust thorough paper trails must learn to trust risk assessments and SME judgment (^[15]). Some organizations may need to build “Critical Thinking” skills in their teams – this includes training on risk analysis, statistical thinking, and cross-functional communication. Documentation policies may need to be relaxed to allow more informal testing records without fear of audit objections. Over time, organizations that successfully adopt CSA will likely become more agile and innovative, as development cycles shorten without sacrificing compliance.

• Technology Enablement: Automation tools for testing, electronic recordkeeping, and monitoring can support digital transformation, but cloud-hosted GxP systems require a manufacturer-specific assurance case. For medical-device production or quality-management-system software within FDA CSA’s scope, manufacturers should identify the intended use and applicable requirements, assess relevant configuration, interfaces, infrastructure, supplier evidence, and risks, and select assurance activities commensurate with risk. FDA permits consideration of validation activities performed by developers, suppliers, and cloud service providers, but that evidence does not itself establish that the regulated user’s system is fit for its intended use (^[1]). AI/ML uses likewise require an intended-use and risk-based assessment under the requirements that apply to the organization and product.

• Data Integrity and Digital Recordkeeping: While CSA focuses on system assurance, it inherently supports data integrity (ALCOA+) by emphasizing controls over key data processes. GAMP 5 second edition and its Good Practice Guides also stress data integrity by design. Integrating CSA means putting emphasis on the accuracy of critical data (since testing is leaner, data errors become even more critical to catch early).

• Future Research and Standards: The shift to CSA has prompted new training (e.g. ISPE workshops, webinars (^[2])), and we can expect more industry publications. Academic journals on regulatory affairs and informatics may begin to produce empirical studies on CSA implementation outcomes. Standards development organizations (like ISPE, GAMP Community) will likely publish additional guidance (e.g. future Good Practice Guides or case studies) to help companies.

• Risk of Complacency: A cautionary note: risk-based does not mean no testing. Some critics (e.g. McDowall (^[32])) warn that if misapplied, CSA could become a license to do too little. Regulators still require evidence of control, and companies must ensure that the shift in terminology does not become sloppy. Proper governance and audit of the CSA process are needed to sustain quality gains. In practice, a balanced core of traditional controls (such as system change control, user training, audit trails) remains essential.

GAMP 5 and FDA CSA both discuss risk-based computerized-system assurance, but they have different roles. GAMP 5 is industry guidance that organizations may consider within their GxP programs. FDA’s CSA guidance is nonbinding guidance for software used in medical-device production or a medical-device quality management system and should not be treated as a pharmaceutical-manufacturing requirement. Organizations should apply the requirements that govern their products and jurisdictions.

For pharma IT teams, the practical takeaway is that existing GAMP processes may be reviewed and adapted where appropriate. Organizations may strengthen risk-based thinking and focus quality reviews on evidence tied to safety and quality, but FDA CSA does not require pharmaceutical manufacturers to rename validation plans or adopt an “assurance” document format (^[1]). The outcome is expected to be positive: as ISPE notes, firms will maintain compliance while reducing wasted effort, focusing only on what truly matters (^[16]). In our analysis, aligning GAMP 5 with CSA yields a more efficient validation process that still protects patient safety, product quality, and data integrity – the ultimate goals of any GxP system, as both GAMP and the FDA emphasise (^[16]) (^[5]).

Pharma companies may consider risk-based assurance practices for cloud-based and AI-enabled systems after determining the requirements that apply to their products and jurisdictions. FDA CSA's flexibility concerns software used in medical-device production or a medical-device quality management system; it is not a pharmaceutical safe harbor. A risk-based approach may help organizations focus resources on genuine risks, but cost, timeline, and compliance outcomes depend on the organization, system, risk assessment, and applicable requirements.

In summary: GAMP 5 may inform risk-based assurance practices in pharma, while FDA’s CSA guidance applies to software used in medical-device production or a medical-device quality management system. Before relying on CSA concepts, organizations should identify the requirements that apply to their products, operations, and jurisdictions; a risk-based approach may then help focus assurance resources on the risks that matter (^[1]).